Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713091 | 0.84 | ALDH1A1 (0.54) | MAPK1POLBKMT2AALDH1A1KDM4E | |
| SCHEMBL4716756 | 0.82 | ALDH1A1 (0.55) | MAPK1POLBKMT2AALDH1A1KDM4E | |
| SCHEMBL4716717 | 0.82 | ALDH1A1 (0.46) | POLBKMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4716394 | 0.82 | CNR1 (0.52) | MAPK1POLBKMT2AALDH1A1KDM4E | |
| SCHEMBL4715768 | 0.81 | MAPT (0.56) | MAPK1POLBKMT2AALDH1A1MAPT | |
| SCHEMBL4716672 | 0.81 | CNR1 (0.44) | POLBKMT2AALDH1A1RAB9AMAPT | |
| SCHEMBL4716303 | 0.81 | MEN1 (0.51) | MAPK1POLBKMT2AALDH1A1KDM4E | |
| SCHEMBL4714765 | 0.80 | RXFP1 (0.49) | POLBKMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4716780 | 0.80 | ALDH1A1 (0.46) | MAPK1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4714715 | 0.80 | VCAM1 (0.40) | MAPK1KMT2AALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | MAPK1 3513/4885POLB 3790/4885KMT2A 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.